The global organ transplant immunosuppressant drugs market has been going through a rough patch since last few years. The high cost of organ transplantation, coupled with increasing incidences of infection post-transplant, has affected the worldwide market for organ transplant immunosuppressant drugs significantly in recent times.

1. Global Organ Transplant Immunosuppressant
Drugs Market Restrained by High Costs; Market to
Shrink to US$3.2 bn by 2023
The global organ transplant immunosuppressant drugs market is exhibiting a CAGR of -5.0%
within a forecast period from 2015 to 2023. The market was registered at US$5.1 bn in 2014. It
is expected to shrink to US$3.2 bn by the end of 2023, according to a research report released by
Transparency Market Research. The report is titled “Organ Transplant Immunosuppressant Drugs
Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”
Organ transplantation involves surgical removal and transfer of a healthy organ from a living or
dead human body into another individual’s body. Often, it is the only treatment for end stage
organ failure. Use of immunosuppressant drugs post organ transplantation procedures has
increased the success rate of organ transplants. Excess demand coupled with shortage of organ
donors and procedural difficulties leads to different waiting time and success rates for organ
transplantation.
The global organ transplant immunosuppressant drugs market is broadly categorized into drug
class, transplants, and geography. Calcineurin inhibitors, anti-proliferative agents, mTOR
inhibitors, antibodies, and steroids together comprise the organ transplant immunosuppressant
drug class segment. Calcineurin inhibitors was the largest segment and was valued at USD
2,304.0 million in 2014. Over 85% of kidney transplant recipients are prescribed tacrolimus as
maintenance immunosuppressive regimen mainly because of its higher potency and lower
rejection and nephrotoxicity compared to cyclosporine.
Antibodies is anticipated to be the fastest growing segment during the forecast period.
Corticosteroids are administered to patients in high dosages during initial stages of organ
transplantation. The most common corticosteroids used in organ transplantation are oral
prednisone, prednisolone, and methylprednisolone.
Applications for this market include transplantation of kidney, heart, liver, bone marrow, and
lungs. The kidney transplant segment accounted for more than 50% share of the organ transplant
immunosuppressant drugs market in 2014. This segment is expected to maintain its dominance
during the forecast period as availability of kidneys from live and deceased donors is higher as
compared to other organs. Bone marrow transplantation segment is expected to grow at the
fastest CAGR during the forecast period from 2015 to 2023.
Browse Full Research Report on Organ Transplant Immunosuppressant Drugs Market:
http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

2. Geographically, the organ transplant immunosuppressant drugs market has been segmented into
five regions: North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW).
The market is majorly concentrated in the U.S., followed by Europe and Asia, especially China.
According to the WHO, the U.S. was the most attractive country for organ transplantation in
2013, with more than 50% share of kidney transplantation, followed by liver and heart
transplantations.
The dominance was majorly due to improvement in technology, surgical techniques, and
immunosuppressive drugs as well as growing success rate of organ transfer procedures. Growing
medical tourism for organ transplantation in developing regions such as Asia Pacific and Latin
America (due to lower cost) as compared to developed regions helps boost the market in
developing regions. However, decline in the CAGR is anticipated due to imbalance in demand
and supply of donor organs. Requirement of continuous follow-up and risk of infection post
organ transplantation could hamper the market growth and eventually restrict the uptake of
immunosuppressant drugs.
AbbVie, Inc., Astellas Pharma, Inc., Bristol?Myers Squibb Company, F. Hoffmann-La Roche
Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc.,
Novartis Pharmaceuticals Corporation, Pfizer, Inc., and Veloxis Pharmaceuticals A/S. are some
of the major companies operating in the global organ transplant immunosuppressant drugs
market.
Browse Full Press Release on Organ Transplant Immunosuppressant Drugs
Market:
About Us
Transparency Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that
it always reflects the latest trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.
Press Release

3. Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY – 12207,
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com